(Q82928114)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Roberta J Ward

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

David T Dexter

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sarah A Statton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Charlotte Whitmore

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Wolfhardt Freinbichler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Keith F Tipton

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Laura Della Corte

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Robert R Crichton

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

17 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neural Transmission

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

223-231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00702-010-0531-3

18 January 2020

exact match

0 references

cites work

The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

1 reference

12 December 2020

Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation

1 reference

12 December 2020

6-Hydroxydopamine-induced alterations in blood-brain barrier permeability

1 reference

12 December 2020

Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.

1 reference

12 December 2020

Oxidative stress hypothesis in Alzheimer's disease: a reappraisal

1 reference

12 December 2020

Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment

1 reference

12 December 2020

Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials

1 reference

12 December 2020

Increased nigral iron content in postmortem parkinsonian brain.

1 reference

12 December 2020

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

1 reference

12 December 2020

Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

1 reference

12 December 2020

Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease

1 reference

12 December 2020

Oxidative alterations in Alzheimer's disease.

1 reference

12 December 2020

Does neuroinflammation fan the flame in neurodegenerative diseases?

1 reference

12 December 2020

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

1 reference

12 December 2020

The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease

1 reference

12 December 2020

Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics

1 reference

12 December 2020

Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders.

1 reference

12 December 2020

Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects

1 reference

12 December 2020

Potential sources of increased iron in the substantia nigra of parkinsonian patients

1 reference

12 December 2020

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

1 reference

12 December 2020

Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis

1 reference

12 December 2020

Deferoxamine therapy for intracerebral hemorrhage

1 reference

12 December 2020

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

1 reference

12 December 2020

Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior

1 reference

12 December 2020

Nanoparticle and iron chelators as a potential novel Alzheimer therapy

1 reference

12 December 2020

Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo

1 reference

12 December 2020

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia

1 reference

12 December 2020

Role of iron in neurotoxicity: a cause for concern in the elderly?

1 reference

12 December 2020

Selective iron chelation in Friedreich ataxia: biologic and clinical implications.

1 reference

12 December 2020

Intramuscular desferrioxamine in patients with Alzheimer's disease

1 reference

12 December 2020

Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism

1 reference

12 December 2020

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

1 reference

12 December 2020

Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke

1 reference

12 December 2020

Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats

1 reference

12 December 2020

Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content

1 reference

12 December 2020

10.1007/S00702-010-0531-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21165659%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference